Recent Updates
Recently added Catalysts

Savara, Inc.

SVRA
Richly ValuedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$4.92
▲ +0.16 · +3.31%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SVRA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.3552W HIGH $7.00
Volume
1.53 M
Value Traded
6.92 M
Short % Float
42.09%
+2.93%Week
-7.17%1 Month
-14.29%3 Month
-16.89%6 Month
+206.1%5 Year
-99.77%All Time

Cash Data

Unlock SVRA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.01 B
EPS (TTM)
-0.68
P/E Ratio
-
Ent. Value
867.94 M
Total Shares
205.46 M
Float Shares
102.98 M
Insiders
49.88%
Institutions
66.98%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
molgramostim
autoimmune pulmonary alveolar proteinosis (autoimmune PAP)
PDUFABiologicsRespiratory System
Unlock every SVRA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SVRA Catalyst Timeline

Dated clinical, regulatory and corporate events for Savara, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Savara, Inc.

370Total events
3Upcoming
114Tier-1 (high impact)
2010 to 2026Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
MOLBREEVIFiled
T1PDUFA Date
Subscribe to view catalyst details
MOLBREEVIFiled

Event history 50

◆Oral PresentationMolgramostimPresentation
Oral presentation of long-term efficacy and safety results from the open-label period of the IMPALA-2 Phase 3 trial at ERS Congress 2026
autoimmune pulmonary alveolar proteinosis (aPAP)source ↗
◆Poster PresentationMolgramostimPresentation
Poster presentation on exercise capacity, distance walked, and duration of exercise results from the IMPALA-2 Phase 3 trial at ERS Congress 2026
autoimmune pulmonary alveolar proteinosis (aPAP)source ↗
◆R&D DayPresentation
Industry Evening Mini-Symposium on aPAP with key opinion leaders at ERS Congress 2026
autoimmune pulmonary alveolar proteinosis (aPAP)source ↗
●Quarterly UpdateCorporate
Savara reported second quarter 2026 financial results and business update
source ↗
▲Patent GrantedMOLBREEVIFiledIP / Competition
Australian Patent Office granted patent No. 62/990,810 covering liquid formulation of MOLBREEVI
autoimmune PAPsource ↗
◆FDA ApprovalMOLBREEVIFiledFDA Decision
Potential FDA approval of MOLBREEVI
autoimmune pulmonary alveolar proteinosis (autoimmune PAP)source ↗
◆Timing GuidanceMOLBREEVIFiledPresentation
Potential FDA approval if Priority Review granted
autoimmune pulmonary alveolar proteinosissource ↗
◆Management ChangeCorporate
Chief Financial and Administrative Officer transition announced
source ↗
◆Oral PresentationPresentation
Fireside chat at 2026 Jefferies Global Healthcare Conference
source ↗
◆Poster PresentationMolgramostimPresentation
New biomarker data from IMPALA-2 Phase 3 trial presented at ATS 2026
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)source ↗
Unlock the full SVRA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SVRA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30MOLBREEVI Approval Decision BLA
Unlock 11 more SVRA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D38 / 100
Pipeline Score
$31M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 45%
Micro Cap
(rank 297 of 658)
Percentile Rank
Savara, Inc. faces pipeline headwinds (38/100), with $98M risk-adjusted pipeline value, led by Molgramostim in Mycobacterium Infections, Nontuberculous (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Molgramostim Small moleculeNCT04544293Autoimmune Pulmonary Alveolar ProteinosisPhase 3 ACTIVE NOT_RECRUITING 308May 30, 2027
Unlock the SVRA pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SVRA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Molgramostim
BreakthroughFast TrackOrphan
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Phase 32026-05-19retention rate: 94%; patients enrolled: 164; patients completed db: 160; dlco improvement: continuous and sustained improvements; sgrq scores: notable improvements in SGRQ-T and SGRQ-A scoresRead MoreSavara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Read More
Scroll for more · summaries link to the source press release
Unlock every SVRA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SVRA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Lowrance David LOfficer (Chief Financial Officer)Option 75,000 611,032 held$1.59 06/22/2026
Unlock the full SVRA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in SVRA

Fund % of Portfolio Current MV Shares Owned Activity
NEA Management Company, LLC 9.5 % (25 %) 150.74 M 24.47 M
Unlock every fund holding SVRA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SVRA
Shares held by hedge funds each quarter, and who bought or sold.

SVRA Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-10-16
Unlock SVRA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SVRA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SVRA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SVRA ranks across every disease it competes in

Competitive Position is a premium feature
See how SVRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SVRA News

SVRA
Aug 24, 2026
SVRAPhases

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Inc. announced that data from the Phase 3 IMPALA-2 clinical trial of molgramostim will be presented at the ERS Congress 2026. The presentations include one oral and two poster formats, highlighting improvements in lung function, exercise capacity, and quality of life for patients with Autoimmune Pulmonary Alveolar Proteinosis. This recognition underscores the significance of the trial results.

Read more →
SVRA
Aug 20, 2026
SVRAGeneral

Savara Announces New Employment Inducement Grant

Savara Inc. has announced the grant of inducement awards to eight new employees, which includes options to purchase 74,500 shares of common stock and restricted stock units. This move reflects the company's ongoing commitment to growth and its focus on rare respiratory diseases. The awards were granted by the Compensation Committee of Savara's Board of Directors.

Read more →
SVRA
Aug 11, 2026
SVRAGeneral

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Inc. has announced its financial results for the second quarter of 2026, highlighting its focus on rare respiratory diseases. The company is currently awaiting regulatory applications in the U.S., EU, and U.K., with the U.S. being identified as the nearest-term opportunity for advancement. CEO Matt Pauls emphasized the company's strategic direction during this period.

Read more →
SVRA
Jul 30, 2026
SVRAGeneral

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Savara Inc. has received patent grants for its liquid formulation of MOLBREEVI from both the European and Australian Patent Offices. The European patent, numbered 4121000, provides protection until March 2041. This development is significant for Savara as it enhances their market position in treating rare respiratory diseases.

Read more →
SVRA
Jun 8, 2026
SVRAGeneral

Savara Announces Chief Financial and Administrative Officer Transition

Savara has announced a transition in its Chief Financial and Administrative Officer position. The article does not provide specific details regarding the reasons for the transition or the implications for the company. This change reflects ongoing adjustments within the company's leadership structure.

Read more →
SVRA
May 27, 2026
SVRAConferences/Events

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara has announced its participation in the upcoming 2026 Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategic initiatives. Further details regarding the presentation or topics to be covered have not been disclosed.

Read more →
SVRA
May 20, 2026
SVRAPhases
▲ +7.6%on this news

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara presented new biomarker data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS International Conference 2026. The presentation highlighted important findings that could impact future research and treatment strategies for aPAP. Further details on the data and its implications were discussed during the conference.

Read more →
SVRA
May 19, 2026
SVRAPhases

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara presented long-term efficacy and safety data from the ongoing IMPALA-2 Phase 3 clinical trial regarding Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP). The data was shared during a recent presentation. Further details on the findings were not provided in the article.

Read more →
SVRA
May 18, 2026
SVRAPhases

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara has announced new exercise capacity data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP). The data highlights the potential benefits of Molgramostim in improving exercise capacity for patients. Further details on the results and implications were not provided in the announcement.

Read more →
SVRA
May 12, 2026
SVRAConferences/Events

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc. announced its participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference, scheduled for May 19th at NASDAQ headquarters in New York. The management team will engage in a fireside chat, which will be available for live streaming and later replay. Savara focuses on rare respiratory diseases, with its lead program, MOLBREEVI, in Phase 3 development.

Read more →
SVRA
May 12, 2026
SVRAGeneral

Savara Reports First Quarter Financial Results and Provides Business Update

Savara has released its financial results for the first quarter, along with a business update. The report outlines the company's current financial standing and strategic direction moving forward. Specific details regarding revenue, expenses, and future plans were shared, although no significant changes or developments were highlighted.

Read more →
SVRA
Apr 20, 2026
SVRAGeneral

Savara Announces New Employment Inducement Grant - April 17, 2026

Savara Inc. announced the grant of inducement awards to 24 new employees on April 14, 2026. The awards include stock options, restricted stock units, and performance stock units, aimed at encouraging employee retention. These equity awards are part of Savara's 2021 Inducement Equity Incentive Plan and are tied to the employees' continued employment.

Read more →
SVRA
Apr 16, 2026
SVRAFDA Updates

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. announced that the FDA has extended the review period for its molgramostim Biologics License Application (BLA) for autoimmune pulmonary alveolar proteinosis by three months, now set for November 22, 2026. This extension follows the submission of additional information by the company, which the FDA deemed a major amendment. The FDA did not express any safety or efficacy concerns.

Read more →
SVRA
Apr 15, 2026
SVRAConferences/Events

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara Inc. will present new data from the Phase 3 IMPALA-2 clinical trial of molgramostim at the ATS International Conference in May 2026. The presentations include an oral presentation on exercise improvements in aPAP patients and two poster presentations discussing long-term efficacy and biomarker relationships. The company will also host an industry theater focusing on aPAP advancements.

Read more →
SVRA
Apr 7, 2026
SVRAFDA Updates

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara has announced that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI*, aimed at treating Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP). This acceptance marks a significant step forward for the company in bringing this treatment to market. The decision highlights the potential for addressing an unmet medical need in this area.

Read more →
SVRA
Mar 30, 2026
SVRAFDA Updates

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara has announced that the European Medicines Agency has validated its Marketing Authorization Application for MOLBREEVI, a treatment for Autoimmune Pulmonary Alveolar Proteinosis. This validation marks a crucial advancement in the drug's approval process. The company aims to provide a solution for patients suffering from this rare autoimmune disease.

Read more →

About Savara, Inc.

Austin, TX 70 employees savarapharma.com
Headquarters6836 BEE CAVE ROAD, AUSTIN, TX, 78746
BIOPHARMAWATCH ELITE PLUS
Trade the next SVRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime